NIH Workshop Presentations: Research Needs for the Design and Analysis of Surrogate Endpoints in Clinical Trials

NIH Workshop:
Research Needs for the Design and Analysis
Of Surrogate Endpoints in Clinical Trials

Surrogate Endpoints in Chronic Disease Prevention: How Comprehensive Do they Need to Be?	Ross Prentice
Surrogate Markers Workshop: Presentation	Arthur Schatzkin
A Meta-Analytic Framework for Assessing Surrogate Outcomes	R. J. Carroll M.H. Gail H. C. vonHouwelingen
Intermediate Endpoints in Cancer Treatment Studies	Richard Simon
Discussion of: Intermediate Endpoints in Cancer Treatment Studies	John Crowley
Joint Modeling of Longitudinal Measurements and Event Histories	Peter Diggle Rob Henderson Jane Xu Scott Zeger
Prevention Models for Alcoholism: Implications for Assessing Treatment Effects That Vary Across Surrogate Endpoint Trajectory Classes	Bengt Muthen
Second-Generation Structural Equation Modeling with a Combination of Categorical and Continuous Latent Variables: New Opportunities for Latent Class/Latent Growth Modeling	Bengt Muthen
Coronary Flow as a Surrogate Endpoint in Phase II Studies of Myocardial Infarction	Keaven Anderson
Equal Risk for Equal Measures? Cardiovascular Disease, Blood Pressure and Lipids	Barry Davis
Evaluation of Surrogate Endpoints in HIV Clinical Trials	Michael Hughes
Surrogate Endpoints (Markers)	Michael Hughes
Vaccine Correlates of Immunity	Robert Kohberger
Meta-Analysis and Endpoints in Advanced Colorectal Cancer	Pascal Piedbois Marc Buyse Geert Molenberghs
Validation of Surrogate Endpoints with Data from Randomized Trials	Pascal Piedbois Marc Buyse Geert Molenberghs
Validation of Surrogate Endpoints from Multiple Trials	Pascal Piedbois Marc Buyse Geert Molenberghs